ArticleOncotarget2016

Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors.

Jürgen Borlak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.